Zhou Xufeng, Chang Cong, Zhou Yang, Sun Lu, Xiang Hua, Zhao Sijie, Ma Liwei, Zheng Guohua, Liu Mingzhu, Wei Hua
State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, China.
J Mater Chem B. 2017 Jun 21;5(23):4443-4454. doi: 10.1039/c7tb00261k. Epub 2017 Mar 15.
Polymeric delivery vehicles can improve the safety and efficacy of chemotherapy drugs by facilitating preferential tumor delivery. Double hydrophilic block copolymer (DHBC)-based prodrugs are considered as ideal candidates for drug delivery due to the elegant integration of benefits from both structures including polymeric prodrugs' superior protection and minimal premature drug release using covalent links and a DHBC-based "green" self-assembly strategy by a simple stimulus in a pure aqueous phase without the use of any organic solvent. Clearly, the location of drug molecules in the polymeric prodrugs has exerted a significant effect on their therapeutic efficiency. However, there has been no published data so far, to our knowledge, reporting the effect of drug-conjugated sites on its therapeutic efficacy, as well as some basic guidelines that can be followed to direct the future design of polymeric prodrugs. To this end, herein a thermo-sensitive DHBC, poly(N-(2-hydroxypropyl) methacrylamide)-b-poly(N-isopropyl acrylamide) (P(HPMA)-b-P(NIPAAm)), was designed and synthesized by successive reversible addition and fragmentation chain transfer (RAFT) polymerizations, and was chosen as a platform to clarify this issue. An anti-cancer drug, doxorubicin (DOX) was conjugated to the hydrophilic PHPMA block and the temperature-responsive P(NIPAAm) block, respectively, through a pH-liable hydrazone bond to fabricate two different types of polymeric prodrugs with the drug tethered to the micellar hydrophilic PHPMA shell or encapsulated within the hydrophobic P(NIPAAm) core upon temperature elevation above its lower critical solution temperature (LCST). A detailed comparison study was carried out to investigate which structure exhibits better properties and higher therapeutic efficacy in terms of micellar size, stability, cellular uptake, drug loading capacity, drug release behaviors and cell viability. The results showed the self-assembly of both DHBC-based prodrugs into well-dispersed spherical micelles with similar average hydrodynamic diameters (D) around 150 nm in phosphate buffer (PBS, pH 7.4) at 37 °C, but a higher drug loading content (DLC), and enhanced pH-mediated drug release, i.e., much accelerated drug release at pH 5.0, while slower at pH 7.4, as well as enhanced cytotoxicity when the drug was conjugated to the hydrophilic shell of the micelles. The guidelines obtained in this study are thus believed to direct the future design and development of polymeric prodrugs for efficient cancer therapy.
聚合物递送载体可通过促进化疗药物优先递送至肿瘤部位来提高其安全性和疗效。基于双亲水嵌段共聚物(DHBC)的前药被认为是理想的药物递送候选物,这是因为其巧妙地整合了两种结构的优点,包括聚合物前药的卓越保护作用以及通过共价连接实现的最小程度的药物过早释放,以及基于DHBC的“绿色”自组装策略,即在纯水性相中通过简单刺激而无需使用任何有机溶剂。显然,聚合物前药中药物分子的位置对其治疗效果产生了显著影响。然而,据我们所知,迄今为止尚无公开数据报道药物共轭位点对其治疗效果的影响,以及可用于指导未来聚合物前药设计的一些基本准则。为此,本文通过连续可逆加成-断裂链转移(RAFT)聚合反应设计并合成了一种热敏性DHBC,聚(N-(2-羟丙基)甲基丙烯酰胺)-b-聚(N-异丙基丙烯酰胺)(P(HPMA)-b-P(NIPAAm)),并选择其作为平台来阐明这一问题。一种抗癌药物阿霉素(DOX)分别通过对pH敏感的腙键与亲水性PHPMA嵌段和温度响应性P(NIPAAm)嵌段共轭,以制备两种不同类型的聚合物前药,当温度升高至其低临界溶液温度(LCST)以上时,药物分别连接在胶束的亲水性PHPMA外壳上或包裹在疏水性P(NIPAAm)核内。进行了详细的比较研究,以调查哪种结构在胶束尺寸、稳定性、细胞摄取、载药量、药物释放行为和细胞活力方面表现出更好的性能和更高的治疗效果。结果表明,在37°C的磷酸盐缓冲液(PBS,pH 7.4)中,两种基于DHBC的前药均自组装成平均流体力学直径(D)约为150 nm的分散良好的球形胶束,但当药物连接在胶束的亲水性外壳上时,载药量(DLC)更高,pH介导的药物释放增强,即在pH 5.0时药物释放加速,而在pH 7.4时较慢,并且细胞毒性增强。因此,本研究中获得的准则被认为可指导未来用于高效癌症治疗的聚合物前药的设计和开发。